checkmate-214: nivolumab/ipilimumab for mrcc?
Published 6 years ago • 538 plays • Length 3:07Download video MP4
Download video MP3
Similar videos
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
2:08
nivolumab with ipilimumab for mrcc
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
4:46
sbrt in combination with ipilimumab/nivolumab in mrcc
-
2:00
nivolumab and ipilimumab in mrcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:49
bradley mcgregor, md, discusses checkmate-214 investigating nivolumab ipilimumab in rcc patients
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
1:17
dr. hammers on the checkmate-214 study for rcc
-
5:26
mrcc: impact of cabosun and checkmate-214
-
1:06
dr. mckay discusses the checkmate-214 trial in rcc
-
2:01
michael atkins, md, discusses checkmate-214 investigating nivolumab ipilimumab in rcc patients